Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-6 of 6 for your search:
Drug:
gimatecan
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Gimatecan in Patients With Recurrent or Progressive Primary Malignant Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0403029-01
, SIGMATAU-ST-01-402, NCT00087061
2.
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLBQ707A1101
, NCT00410358
3.
Dose-Escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLBQ707A2101
, NCT00420485
4.
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Closed
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLBQ707A1101E1
, NCT00441610
5.
Extension to Dose-Escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLBQ707A2101E1
, NCT00462163
6.
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLBQ707A1103
, NCT00487058
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute